Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...

In general, there are three types of caulk that are commonly used for DIY projects: silicone, acrylic latex, and polyurethane-based caulk. After applying the caulk, check the side of the tube or ...

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease. The Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L-rknd ...

WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug ...

On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...

Neffy for severe allergic reactions and Dupixent for chronic obstructive pulmonary disease (COPD), which all gained FDA approval this year. These medications are "slated to make a big clinical ...

However, the FDA noted in its approval announcement that there was no statistically significant difference regarding overall survival. The most common side effects experienced by at least 20% of ...

Dec. 17, 2024 -- The FDA last week approved Nemluvio for treating moderate to severe atopic dermatitis, a type of eczema, in people aged 12 or older. Nemluvio is to be used with topical ...

The FDA has approved cosibelimab, a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. It is the first and only PD-L1 blocker approved to treat ...

Dec 13 (Reuters) - The U.S Food and Drug Administration said on Friday it has approved Checkpoint Therapeutics ... into other areas of the body, the FDA said. Unloxcyt is part of a class called ...

The US Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the treatment of adults with ALK-positive locally advanced or metastatic non-small cell ...